Clinicopathological features of primary fallopian tube carcinoma: A single institution experience

C. A. Papadimitriou; S. Markaki; E. Lianos; P. Peitsidis; G. Vourli; N. Nikitas; G. Vlachos; A. Rodolakis; A. Antsaklis; M. A. Dimopoulos

Clinicopathological features of primary fallopian tube carcinoma: A single institution experience

C. A. Papadimitriou, S. Markaki, E. Lianos, P. Peitsidis, G. Vourli, N. Nikitas, G. Vlachos, A. Rodolakis, A. Antsaklis, M. A. Dimopoulos

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose of investigation: Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors. Methods: We retrospectively analyzed 26 patients. Tissue blocks were reviewed and sections were stained for vascular endothelial growth factor (VEGF), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and progesterone receptors (PgR). Results: Reactivity for VEGF, ER, PgR, MMP-2, MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 23% and 8% of specimens, respectively. None of the markers studied displayed prognostic significance. Regarding clinical prognostic factors, the hazard ratio (HR) for progression and death for patients with tumor residuum > 2 cm was 5.24 (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was not found to be statistically significant. Conclusion: None of the biomarkers studied seems to influence survival. Early-stage disease and optimal debulking are associated with improved outcome.

Original language	English
Pages (from-to)	389-395
Number of pages	7
Journal	European Journal of Gynaecological Oncology
Volume	30
Issue number	4
Publication status	Published - 2009

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Keywords

First-line chemotherapy
Immunohistochemistry
Primary fallopian tube cancer
Prognostic factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{1c5a87ae70214e8c946b0c616244380e,

title = "Clinicopathological features of primary fallopian tube carcinoma: A single institution experience",

abstract = "Purpose of investigation: Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors. Methods: We retrospectively analyzed 26 patients. Tissue blocks were reviewed and sections were stained for vascular endothelial growth factor (VEGF), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and progesterone receptors (PgR). Results: Reactivity for VEGF, ER, PgR, MMP-2, MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 23% and 8% of specimens, respectively. None of the markers studied displayed prognostic significance. Regarding clinical prognostic factors, the hazard ratio (HR) for progression and death for patients with tumor residuum > 2 cm was 5.24 (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was not found to be statistically significant. Conclusion: None of the biomarkers studied seems to influence survival. Early-stage disease and optimal debulking are associated with improved outcome.",

keywords = "First-line chemotherapy, Immunohistochemistry, Primary fallopian tube cancer, Prognostic factors",

author = "Papadimitriou, {C. A.} and S. Markaki and E. Lianos and P. Peitsidis and G. Vourli and N. Nikitas and G. Vlachos and A. Rodolakis and A. Antsaklis and Dimopoulos, {M. A.}",

year = "2009",

language = "English",

volume = "30",

pages = "389--395",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "MRE Press",

number = "4",

}

TY - JOUR

T1 - Clinicopathological features of primary fallopian tube carcinoma

T2 - A single institution experience

AU - Papadimitriou, C. A.

AU - Markaki, S.

AU - Lianos, E.

AU - Peitsidis, P.

AU - Vourli, G.

AU - Nikitas, N.

AU - Vlachos, G.

AU - Rodolakis, A.

AU - Antsaklis, A.

AU - Dimopoulos, M. A.

PY - 2009

Y1 - 2009

N2 - Purpose of investigation: Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors. Methods: We retrospectively analyzed 26 patients. Tissue blocks were reviewed and sections were stained for vascular endothelial growth factor (VEGF), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and progesterone receptors (PgR). Results: Reactivity for VEGF, ER, PgR, MMP-2, MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 23% and 8% of specimens, respectively. None of the markers studied displayed prognostic significance. Regarding clinical prognostic factors, the hazard ratio (HR) for progression and death for patients with tumor residuum > 2 cm was 5.24 (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was not found to be statistically significant. Conclusion: None of the biomarkers studied seems to influence survival. Early-stage disease and optimal debulking are associated with improved outcome.

AB - Purpose of investigation: Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors. Methods: We retrospectively analyzed 26 patients. Tissue blocks were reviewed and sections were stained for vascular endothelial growth factor (VEGF), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and progesterone receptors (PgR). Results: Reactivity for VEGF, ER, PgR, MMP-2, MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 23% and 8% of specimens, respectively. None of the markers studied displayed prognostic significance. Regarding clinical prognostic factors, the hazard ratio (HR) for progression and death for patients with tumor residuum > 2 cm was 5.24 (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was not found to be statistically significant. Conclusion: None of the biomarkers studied seems to influence survival. Early-stage disease and optimal debulking are associated with improved outcome.

KW - First-line chemotherapy

KW - Immunohistochemistry

KW - Primary fallopian tube cancer

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=68849105112&partnerID=8YFLogxK

M3 - Article

C2 - 19761129

AN - SCOPUS:68849105112

SN - 0392-2936

VL - 30

SP - 389

EP - 395

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

IS - 4

ER -

Clinicopathological features of primary fallopian tube carcinoma: A single institution experience

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this